nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

08.01.2018 | case report

Local therapy of stage IV renal cell cancer: a case report

verfasst von: Muna Ferner, Andrea Vera Keck, Dora Niedersüß-Beke, Kathrin Strasser-Weippl

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Summary

This mini-review and case report demonstrates how systemic and local treatments work synergistically for patients with metastatic renal cell carcinoma (mRCC). Although new targeted and immunotherapies have revolutionized the treatment armamentarium of mRCC and dramatically improved patients’ prognosis, local treatment remains an important part of therapy. Here, we report on a patient who benefitted enormously from the combination and interaction of both therapeutic approaches, and we summarize the literature and guidelines that supported our treatment decisions in this case.

Vorheriger Artikel Practice-changing developments in early use of chemohormonal therapy in metastatic prostate cancer

Nächster Artikel PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.CrossRefPubMed

Flanigan RC, Yonover PM. The role of radical nephrectomy in metastatic renal cell carcinoma. Semin Urol Oncol. 2001;19(2):98–102.PubMed

Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966–70.CrossRefPubMed

Ulka N, Vaishampayan MD. The role of nephrectomy for kidney cancer in the era of targeted and immune therapies. Am Soc Clin Oncol Educ Book. 2016;35:e16–e20.

Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Supplement 5):v58.CrossRefPubMed

Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor—targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–9.CrossRefPubMed

Heng DY, Choueiri TK, Rini BI, et al. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol. 2014;25(1):149–54.CrossRefPubMedPubMedCentral

Motzer RJ, Hutson TE, McCann L, et al. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med. 2014;370(18):1769–70.CrossRefPubMed

Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584–90.CrossRefPubMedPubMedCentral

10.

Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–8.CrossRefPubMed

11.

Kavolius JP, Mastorakos DP, Pavlovich C, et al. Resection of metastatic renal cell carcinoma. J Clin Oncol. 1998;16(6):2261–6.CrossRefPubMed

12.

Alt AL, Boorjian SA, Lohse CM, et al. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer. 2011;117(13):2873–82.CrossRefPubMed

13.

Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422.CrossRefPubMed

14.

Morimoto M, Numata K, Kondou M, et al. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer. 2010;116(23):5452–60.CrossRefPubMed

15.

Atzpodien J, Reitz M. Metastatic renal carcinoma long-term survivors treated with s. c. interferon-alpha and s. c. interleukin-2. Cancer Biother Radiopharm. 2005;20(4):410–6.CrossRefPubMed

16.

Albiges L, Oudard S, Negrier S, et al. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol. 2012;30(5):482–7.CrossRefPubMed

17.

Ornstein MC, Wood LS, Elson P, et al. A phase II study of intermittent Sunitinib in previously untreated patients with metastatic renal cell carcinoma. J Clin Oncol. 2017;35(16):1764–9.CrossRefPubMed

18.

Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–56.CrossRefPubMed

19.

Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–82.CrossRefPubMed

20.

Gibney GT, Aziz SA, Camp RL, et al. c‑Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol. 2013;24(2):343–9.CrossRefPubMed

21.

Zhou L, Liu XD, Sun M, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2016;35(21):2687–97.CrossRefPubMed

22.

Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917–27.CrossRefPubMed

23.

Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931–9.CrossRefPubMed

24.

Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14(6):552–62.CrossRefPubMed

25.

Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33(13):1430–7.CrossRefPubMed

26.

Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advancedrenal-cell carcinoma. N Engl J Med. 2015;373:1803–13.CrossRefPubMedPubMedCentral

Titel: Local therapy of stage IV renal cell cancer: a case report
verfasst von: Muna Ferner
Andrea Vera Keck
Dora Niedersüß-Beke
Kathrin Strasser-Weippl
Publikationsdatum: 08.01.2018
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 1/2018
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-017-0376-7

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Short overview on the current standard of treatment in newly diagnosed multiple myeloma

ESMO 2017—my personal highlights

My burning issues in the neoadjuvant treatment for breast cancer

Anti-angiogenic therapies in brain metastases

Novel guidelines on surveillance for breast cancer, cardiomyopathy, male gonadotoxicity, and premature ovarian insufficiency from the PanCare and International Guideline Harmonization Group on long-term follow-up after cancer in childhood

Uro-oncology 2018: new horizons, new treatments, better outcomes